RT Journal Article
SR Electronic
T1 Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.26.20112649
DO 10.1101/2020.05.26.20112649
A1 Williams, Ross D.
A1 Markus, Aniek F.
A1 Yang, Cynthia
A1 Salles, Talita Duarte
A1 DuVall, Scott L.
A1 Falconer, Thomas
A1 Jonnagaddala, Jitendra
A1 Kim, Chungsoo
A1 Rho, Yeunsook
A1 Williams, Andrew
A1 Alberga, Amanda
A1 An, Min Ho
A1 Aragón, María
A1 Areia, Carlos
A1 Burn, Edward
A1 Choi, Young Hwa
A1 Drakos, Iannis
A1 Fernandes Abrahão, Maria Tereza
A1 Fernández-Bertolín, Sergio
A1 Hripcsak, George
A1 Kaas-Hansen, Benjamin Skov
A1 Kandukuri, Prasanna L
A1 Kors, Jan A.
A1 Kostka, Kristin
A1 Liaw, Siaw-Teng
A1 Lynch, Kristine E.
A1 Machnicki, Gerardo
A1 Matheny, Michael E.
A1 Morales, Daniel
A1 Nyberg, Fredrik
A1 Park, Rae Woong
A1 Prats-Uribe, Albert
A1 Pratt, Nicole
A1 Rao, Gowtham
A1 Reich, Christian G.
A1 Rivera, Marcela
A1 Seinen, Tom
A1 Shoaibi, Azza
A1 Spotnitz, Matthew E
A1 Steyerberg, Ewout W.
A1 Suchard, Marc A.
A1 You, Seng Chan
A1 Zhang, Lin
A1 Zhou, Lili
A1 Ryan, Patrick B.
A1 Prieto-Alhambra, Daniel
A1 Reps, Jenna M.
A1 Rijnbeek, Peter R.
YR 2020
UL http://medrxiv.org/content/early/2020/07/27/2020.05.26.20112649.abstract
AB Objective To develop and externally validate COVID-19 Estimated Risk (COVER) scores that quantify a patient’s risk of hospital admission (COVER-H), requiring intensive services (COVER-I), or fatality (COVER-F) in the 30-days following COVID-19 diagnosis.Methods We analyzed a federated network of electronic medical records and administrative claims data from 14 data sources and 6 countries. We developed and validated 3 scores using 6,869,127 patients with a general practice, emergency room, or outpatient visit with diagnosed influenza or flu-like symptoms any time prior to 2020. The scores were validated on patients with confirmed or suspected COVID-19 diagnosis across five databases from South Korea, Spain and the United States. Outcomes included i) hospitalization with pneumonia, ii) hospitalization with pneumonia requiring intensive services or death iii) death in the 30 days after index date.Results Overall, 44,507 COVID-19 patients were included for model validation. We identified 7 predictors (history of cancer, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, hyperlipidemia, kidney disease) which combined with age and sex discriminated which patients would experience any of our three outcomes. The models achieved high performance in influenza. When transported to COVID-19 cohorts, the AUC ranges were, COVER-H: 0.69-0.81, COVER-I: 0.73-0.91, and COVER-F: 0.72-0.90. Calibration was overall acceptable.Conclusions A 9-predictor model performs well for COVID-19 patients for predicting hospitalization, intensive services and fatality. The models could aid in providing reassurance for low risk patients and shield high risk patients from COVID-19 during de-confinement to reduce the virus’ impact on morbidity and mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This project is funded by the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direcció General de Recerca i Innovació en Salut. The University of Oxford received a grant related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201), and partial support from the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. DPA is funded through a NIHR Senior Research Fellowship (Grant number SRF-2018-11-ST2-004). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. AP-U is supported by Fundacion Alfonso Martin Escudero and the Medical Research Council (grant numbers MR/K501256/1, MR/N013468/1). BSKH is funded through Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001). This work was also supported by the Bio Industrial Strategic Technology Development Program (20001234) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. This project is part funded by the UNSW RIS grant. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All databases obtained IRB approval or used deidentified data that was considered exempt from IRB approval. Informed consent was not necessary at any site.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not publicly available due to patient privacy concerns.